Semaglutide, manufactured by Novo Nordisk, known by its brand name Wegovy, for weight loss and Ozempic, for diabetes management, harnesses the power of GLP-1 receptor agonists, to modulate blood sugar and facilitate weight management
ModifyHealth ModifyHealth provides fully prepared, heat-and-eat meals that accommodate typical dietary patterns for gut health conditions
The FDAs warning for Hims & Hers focused on how compounded GLP-1 products were being promoted
Compound Identity & Classification Receptor Pathway Context (GLP-1) Peer-reviewed literature describes semaglutide within GLP-1 receptor pharmacology
Conditions such as lupus, Guillain-Barre syndrome, rheumatoid arthritis, and Sjorgens syndrome can also result in nerve damage